TY - JOUR T1 - Coagulopathy in COVID-19 JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med DO - 10.3949/ccjm.87a.ccc024 AU - Simon R. Mucha AU - Siddharth Dugar AU - Keith McCrae AU - Douglas E. Joseph AU - John Bartholomew AU - Gretchen Sacha AU - Michael Militello Y1 - 2020/05/14 UR - http://www.ccjm.org/content/early/2020/05/12/ccjm.87a.ccc024.abstract N2 - COVID-19-associated coagulopathy is common in patients with COVID-19, causing high rates of thrombotic complications that increase the morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings and correlate with severity of illness and risk of thrombosis. Aggressive VTE prophylaxis is paramount for all patients with COVID-19. Patients with very high D-dimer levels (6 times the upper limit of normal, greater than 3,000 ng/mL) have the greatest risk of thrombosis and may benefit from active screening and more intensive VTE prophylaxis. ER -